ArticleUrologie (Heidelberg, Germany)2026
[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus].
Article in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment options for metastatic prostate cancer have evolved and diversified considerably in recent years. In the hormone-sensitive setting (mHSPC), the combination of androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) or abiraterone + prednis(ol)one (Abi), optionally combined with docetaxel, represents the current standard of care. Prior therapy, the principle of switching the mechanism of action, and the patient's individual molecular genetic profile substantially influence treatment selection in the metastatic castration-resistant setting (mCRPC). Testing for genes involved in homologous recombination repair (HRR), particularly BRCA1/2, is essential for the indication of poly(ADP-ribose) polymerase inhibitors (PARPI), which can be used as monotherapy or in combination with an ARPI/Abi, and has prognostic as well as familial implications. Radioligand therapy with lutetium (
Indexed as
Identifiers
41973209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.